Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
Laboratory for Marine Drugs and Bioproducts of Qingdao, National Laboratory for Marine Science and Technology (QNLM), 1 Wenhai Road, Qingdao 266237, China.
Mar Drugs. 2018 Mar 31;16(4):115. doi: 10.3390/md16040115.
Liphagal and frondosin B are two marine-derived secondary metabolites sharing a very similar polyfused-benzofuran skeleton. The two tetracyclic meroterpenoids were isolated from marine sponges, both featuring a 6-5-7-6 fused ring system. A preliminary bioactive study shows that (+)-liphagal is a selective kinase (PI3K α) inhibitor, while (+)-frondosin B is shown to inhibit the binding of the cytokine interleukin-8 (IL-8) to its receptor, CX-CLR1/2. The unique structures and interesting biological profiles of these two meroterpenoids have attracted considerable attention from synthetic chemists. Herein we summarize the synthetic efforts with respect to (+)-liphagal and (+)-frondosin B during the past two decades.
利法加尔和佛朗多辛 B 是两种海洋来源的次生代谢产物,它们共享一个非常相似的多稠合苯并呋喃骨架。这两种四环倍半萜类化合物是从海洋海绵中分离出来的,都具有 6-5-7-6 稠合环系统。初步的生物活性研究表明,(+)-利法加尔是一种选择性激酶(PI3Kα)抑制剂,而 (+)-佛朗多辛 B 被证明可以抑制细胞因子白细胞介素-8(IL-8)与其受体 CX-CLR1/2 的结合。这两种倍半萜类化合物独特的结构和有趣的生物学特征引起了合成化学家的极大关注。本文总结了过去 20 年来 (+)-利法加尔和 (+)-佛朗多辛 B 的合成研究进展。